# 2025-04020: RIOMET Metformin Solution Safe, Generics Can Proceed

2025-04020, Determination That RIOMET (Metformin Hydrochloride) Oral Solution, 500 Milligrams/5 Milliliters Has Not Been Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-03-13, effective 2025-03-07; PRIA reads it as touching household money (as of 2026-09-30).

- Canonical: https://policyrisk.com/federal-register/2025-04020
- As of: 2026-09-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-04020
- Title: Determination That RIOMET (Metformin Hydrochloride) Oral Solution, 500 Milligrams/5 Milliliters Has Not Been Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 11991
- Published: 2025-03-13
- Effective: 2025-03-07
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-30

## In one line

RIOMET Metformin Solution Safe, Generics Can Proceed

## Summary

The FDA has confirmed that RIOMET (metformin hydrochloride) oral solution hasn’t been taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they meet the rules. Patients and pharmacies can keep counting on this medicine without any interruptions or extra costs.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that RIOMET (metformin hydrochloride) Oral Solution, 500 milligrams (mg)/5 milliliters (mL) has not been withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generic approvals for RIOMET can continue: benefit, medium. The FDA determined that RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL, has not been withdrawn from sale for reasons of safety or effectiveness. Because of that determination, the Agency will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that re…
- Patients and pharmacies retain access without interruption: benefit, medium. You (patients and pharmacies) can continue to rely on RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL, and generic versions may still be approved, which the FDA says avoids interruptions or extra costs. The sponsor reported the product was withdrawn from sale as of November 2019, but FD…
- ANDA applicants may need updated labeling: cost, low. The FDA stated that if it determines that labeling for RIOMET should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. This means generic applicants referencing RIOMET might be asked to update product labeling to comply with current requirements.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-04020 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/13/2025-04020/determination-that-riomet-metformin-hydrochloride-oral-solution-500-milligrams5-milliliters-has-not)
- [2025-04020 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-13/pdf/2025-04020.pdf)

## Related
- [Previous: 2025-04019, Information Collection; Certain Federal Acquisition Regulation Part 32 Requirem…](https://policyrisk.com/federal-register/2025-04019)
- [Next: 2025-04021, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; Gomekli (m…](https://policyrisk.com/federal-register/2025-04021)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-04020 (as of 2026-09-30).
